Page 65 - Read Online

Page 12 of 12 Porta et al. J Cancer Metastasis Treat 2021;7:49 https://dx.doi.org/10.20517/2394-4722.2021.86

Med 2021;384:829-41. DOI PubMed
4. Motzer RJ, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J
Med 2021;384:1289-300. DOI PubMed
5. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med
2019;380:1103-15. DOI PubMed PMC
6. E S M O G u i d e l i n e s C o m m i t t e e . e U p d a t e - r e n a l c e l l c a r c i n o m a t r e a t m e n t r e c o m m e n d a t i o n s
https://www.esmo.org/guidelines/genitourinary-cancers/renal-cell-carcinoma/eupdate-renal-cell-carcinoma-treatment-
recommendations-3 [Last accessed on 8 Jul 2021].
7. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune
checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol 2019;76:151-6.
DOI PubMed
®
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ). Kidney Cancer, Version 3.2021. Available from:
https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. [Last accessed on 12 Aug 2021].
9. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. DOI
PubMed
10. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell
Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141-8. DOI PubMed PMC
11. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell
carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370-
85. DOI PubMed PMC
12. Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus
ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer 2020;8:e000891. DOI PubMed PMC
13. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell
carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079. DOI PubMed PMC
14. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus Axitinib versus Sunitinib monotherapy as first-line treatment of
advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol
2020;21:1563-73. DOI PubMed
15. Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell
carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin
Oncol 2021;39:308. DOI
16. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib
versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31:1030-9. DOI PubMed
17. Rofi E, Del Re M, Arrigoni E, et al. Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. Crit
Rev Oncol Hematol 2020;154:102891. DOI PubMed
18. Porta C, Cosmai L, Rizzo M. Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune
checkpoint inhibitors: where do we stand? Curr Opin Urol 2021;31:236-41. DOI PubMed
19. Bracarda S, Sisani M, Marrocolo F, Hamzaj A, del Buono S, De Simone V. GOAL: an inverse toxicity-related algorithm for daily
clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol 2014;89:386-93. DOI PubMed